Sign In
Buy EDSA
$6.81
-0.540 (-7.35%)
At Close: Jun 22, 2026
Edesa Biotech to Participate in Barclays Global Healthcare Conference
08:45am, Thursday, 07'th Mar 2024
TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
Edesa Biotech to Participate in Upcoming Dermatology Meetings
04:30pm, Monday, 04'th Mar 2024
TORONTO, ON / ACCESSWIRE / March 4, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
04:15pm, Friday, 09'th Feb 2024
TORONTO, ON / ACCESSWIRE / February 9, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory dis
Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week
04:15pm, Thursday, 04'th Jan 2024
TORONTO, ON / ACCESSWIRE / January 4, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory dise
Edesa Biotech Reports Fiscal Year 2023 Results
04:10pm, Friday, 15'th Dec 2023
TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory di
Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study
04:05pm, Monday, 20'th Nov 2023
1.0% Formulation Reached Primary Endpoint with Statistical Significance Full Analysis Identified Additional Efficacy Signals TORONTO, ON / ACCESSWIRE / November 20, 2023 / Edesa Biotech, Inc. (NASDAQ:
Edesa Biotech to Present at Dermatology Drug Development Summit
04:05pm, Thursday, 26'th Oct 2023
TORONTO, ON / ACCESSWIRE / October 26, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug
09:10am, Wednesday, 25'th Oct 2023
TORONTO, ON / ACCESSWIRE / October 25, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that He
Edesa Biotech Secures $10 Million Credit Facility with Company Founder
12:15pm, Thursday, 12'th Oct 2023
Revolving Line of Credit to Support Completion of Government-Funded ARDS Study TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa", or the "Company"), a clinical-s
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
12:10pm, Thursday, 12'th Oct 2023
TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitmen
Edesa Biotech Announces One-for-Seven Reverse Share Split
09:00am, Tuesday, 10'th Oct 2023
TORONTO, ON / ACCESSWIRE / October 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa" or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseas
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
08:15am, Thursday, 28'th Sep 2023
Company's host-directed therapeutic, EB05 (paridiprubart), demonstrated a statistically significant mortality reduction among critically ill patients with severe respiratory disease TORONTO, ON / ACCE
Edesa Biotech Reports Fiscal Third Quarter 2023 Results
04:15pm, Wednesday, 09'th Aug 2023
TORONTO, ON / ACCESSWIRE / August 9, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial
Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference
09:00am, Wednesday, 26'th Jul 2023
TORONTO, ON / ACCESSWIRE / July 26, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the c
Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting
04:10pm, Thursday, 16'th Mar 2023
TORONTO, ON / ACCESSWIRE / March 16, 2023 / Edesa Biotech, Inc. announced today that the company has been selected to present clinical trial data from a Phase 2B multi-dose study of its EB01 drug cand
